Hook / Thesis
Rocket Lab (RKLB) sits at an unusual intersection: a fast-growing space systems company that still trades like a high-growth software name. The company's announced $8 billion plan to acquire Iridium Communications is the clearest path to near-term profitability - management says the deal should produce substantial EBITDA uplift - but the transaction has a live Government Accountability Office protest and broader integration risk that make the outcome binary.
We like RKLB on a measured long trade around the deal timeline. If Iridium closes and synergies materialize, Rocket Lab's EBITDA and free cash flow profile should change materially, justifying a rerating from its current, premium multiples. If the protest drags the deal or forces material concessions, shares can trade sharply lower. This is a tactical, mid-term long (45 trading days) with an optional longer hold if the deal clears.
What Rocket Lab Does and Why the Market Should Care
Rocket Lab operates two main businesses: Launch Services and Space Systems. Launch Services provides dedicated and rideshare rocket launches. Space Systems designs and manufactures satellites, spacecraft components, and handles on-orbit mission operations. Over the past year Rocket Lab has shifted emphasis to space systems - higher-margin, recurring engineering and on-orbit services - which is where the Iridium assets fit.
The market cares because the Iridium acquisition is not just revenue scale - it is an EBITDA and cash-flow story. Iridium is a cash-generative satellite communications operator with a global L-band constellation and subscription revenue. Folding that into Rocket Lab could convert the combined company into a profitable, free-cash-flow generating platform - a big change from the current profile where the company is still investing heavily in growth.
Evidence and Key Financials
- Recent revenue traction: Rocket Lab reported strong top-line growth with Q2 2026 revenue of $255.89 million - up approximately 62% year-over-year, evidence that the Space Systems pivot is accelerating.
- Balance sheet strength: cash on the balance sheet is roughly $4.03 billion and debt is minimal - debt-to-equity sits near 1% - giving Rocket Lab flexibility to fund the deal or withstand delays.
- Market valuation: the company trades at a very high price-to-sales multiple (current P/S ~62.4x by the latest ratio snapshot) and an enterprise value near $45.89 billion, indicating the market already prices in substantial future cash flows. Forward P/S reported in coverage sits materially lower (about 35.25x), reflecting different forward estimates, but both numbers show a very premium valuation versus typical aerospace peers.
- Cash flow today: free cash flow was negative at about -$371.1 million in the most recently reported period, so the Iridium deal is presented by management as the path to flip cash generation positive.
Valuation Framing
Simplify the framing: at a market capitalization around $42.35 billion and an enterprise value near $45.89 billion, Rocket Lab is being valued like a future steady-state cash generator rather than a still-investing growth business. That premium requires either rapid margin expansion, recurring revenue from Iridium, or repeated operational outperformance. If Iridium contributes significant EBITDA as management projects, the premium becomes defensible. If the deal stalls or integration compresses margins, the multiple looks vulnerable to a sharp re-rating.
Catalysts to Watch
- GAO decision on Rocket Lab's protest of the NASA award (reported 10/04/2026) - any legal/regulatory outcome that delays the Iridium timeline or highlights procurement risk could move shares violently.
- Progress on closing the Iridium transaction - definitive financing updates, shareholder approvals, or closing dates will be step changes to the narrative.
- Quarterly releases showing EBITDA improvement or free cash flow inflection - the market will reward tangible margin improvement more than projections.
- Operational wins for Space Systems (new contracts for IMM Apex solar cell tech or repeatable satellite manufacturing) that demonstrate sustainable revenue streams outside the acquisition.
Trade Plan - Actionable Entry, Stop, Target
We recommend a directional, size-conscious long with the following parameters. This is a high-volatility trade; position sizing should reflect that.
| Trade Item | Value |
|---|---|
| Entry | $71.00 |
| Target | $95.00 |
| Stop Loss | $62.00 |
Horizon: Primary - mid term (45 trading days). The mid-term horizon captures likely near-term legal rulings, initial financing or shareholder votes, and the next quarterly report. If the acquisition clears and early integration headlines are positive, consider extending to long term (180 trading days) to capture further re-rating and run-rate EBITDA realization.
Why these levels? Entry at $71 is close to the recent trading range and provides room for short-term intra-day noise. A stop at $62 limits downside if the market re-prices the deal discount or the protest escalates. The $95 target assumes partial realization of Iridium EBITDA upside and a multiple expansion toward more typical high-growth industrials - not the frothier multiples currently in price, but a realistic re-rating if cash flow turns positive and guidance improves.
Technical and Positioning Context
Short interest is material but moderate - recent settlement figures show roughly 43.5 million shares short with days-to-cover typically around 2-3 days given average volume. Momentum indicators show mild bullish MACD momentum, and the stock recently traded near its 10- and 50-day moving averages. Expect above-average intraday volume around any deal news.
Risks and Counterarguments
- GAO / regulatory delay: The active GAO protest and other procurement disputes could push the transaction past the 2028 launch window or force Rocket Lab to walk away, in which case the valuation premium would likely collapse.
- Integration and synergy execution: Acquiring a cash-generative operator like Iridium is one thing - extracting synergies, servicing legacy obligations and aligning operations is another. Integration missteps could negate projected EBITDA uplift.
- Dilution and financing risk: Even with $4.03 billion in cash and low debt, Rocket Lab may still issue equity or take on contingent obligations to complete the $8 billion deal, diluting existing holders and pressuring the share price.
- Valuation vulnerability: The stock already trades at very premium multiples (P/S > 35x to 60x depending on metric). If growth slows or macro liquidity tightens, multiples could compress sharply even if fundamentals are steady.
- Competition and program losses: Recent headlines show competitors winning major NASA contracts - Blue Origin won a $700 million award - and further losses could damage Rocket Lab's defense/space backlog and credibility on large-government programs.
- Counterargument: One reasonable counterargument is that the market already prices Iridium upside - meaning the deal closing may be mostly baked in. In that scenario, news of a close would produce a modest move unless accompanied by explicit margin and cash flow beats. That argues for waiting for concrete EBITDA guidance rather than speculating solely on closing events.
What Would Change Our Mind
We would turn bearish or step away from this trade if any of the following occur: 1) a sustained deterioration in revenue growth across both segments (Launch and Space Systems) with Q-to-Q revenue misses; 2) explicit signs that Iridium synergies are materially smaller than management projected; 3) a GAO ruling that blocks or meaningfully delays the deal; or 4) a financing package that dilutes shareholders more than communicated ranges.
Conclusion
Rocket Lab is a classic binary trade: the Iridium acquisition can convert the company into a profitable, cash-generative platform and justify a meaningful re-rating - or legal and integration risks can erase that upside quickly. The company's cash position and low leverage make the deal feasible, and recent revenue growth ($255.89M in Q2 2026, +62% YoY) supports the narrative. For traders willing to accept high idiosyncratic risk, a mid-term long at $71 with a $62 stop and a $95 target provides an asymmetric risk-reward to the upside, while keeping losses contained if the wildcard - the GAO protest or a messy integration - makes the deal less attractive.
If the deal clears and Rocket Lab starts to show sustained EBITDA and free cash flow improvement, we would consider adding to a long position and moving stops up to protect gains. Until then, size positions with discipline and be prepared for volatile trading around every piece of deal-related news.